LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Name
Helmholtz Zentrum für Infektionsforschung Repository
Type
Institutional Repository
Items
2335 Publications
Compatibility
OpenAIRE 3.0 (OA, funding)
OAI-PMH
http://hzi.openrepository.com/hzi-oai/request
More information
Detailed data provider information (OpenDOAR)

 

  • Dealing with salinity extremes and nitrogen limitation - an unexpected strategy of the marine bacterium Dinoroseobacter shibae.

    Kleist, Sarah; Ulbrich, Marcus; Bill, Nelli; Schmidt-Hohagen, Kerstin; Geffers, Robert; Schomburg, Dietmar (2017)
    Having the right coping strategy for changes in osmolarity or desiccation is essential for the survival of every cell. So far, nothing is known about compatible solutes and the salt adaptation of the marine Rhodobacteraceae. The family member Dinoroseobacter shibae DFL12(T) is shown here to form the compatible solutes α-glucosylglycerol (GG) and α-glucosylglycerate (GGA). To our knowledge, this is the first experimental evidence for GGA formation within the α-proteobacteria. Together with glu...

    Genetic variation in group A streptococci.

    McMillan, David J; Sriprakash, Kadaba S; Chhatwal, Gursharan S (2007)
    Group A streptococcus (GAS) is responsible for a range of human diseases that vary in their clinical manifestations and severity. While numerous virulence factors have been described, the way these factors interact to promote different streptococcal diseases is less clear. In order to identify multifactorial relationships between GAS and the human host, novel high-throughput techniques such as microarrays are necessary. We have performed comparative studies using custom-designed virulence arr...

    Inhibition of 17β-HSD1: SAR of bicyclic substituted hydroxyphenylmethanones and discovery of new potent inhibitors with thioether linker.

    Abdelsamie, Ahmed S; Bey, Emmanuel; Hanke, Nina; Empting, Martin; Hartmann, Rolf W; Frotscher, Martin (2014)
    Estradiol is the most potent estrogen in humans. It is known to be involved in the development and proliferation of estrogen dependent diseases such as breast cancer and endometriosis. The last step of its biosynthesis is catalyzed by 17β-hydroxysteroid dehydrogenase type 1 (17β- HSD1) which consequently is a promising target for the treatment of these diseases. Recently, we reported on bicyclic substituted hydroxyphenylmethanones as potent inhibitors of 17β-HSD1. The present study focuses on...

    The mycolyltransferase 85A, a putative drug target of Mycobacterium tuberculosis: development of a novel assay and quantification of glycolipid-status of the mycobacterial cell wall.

    Elamin, Ayssar A; Stehr, Matthias; Oehlmann, Wulf; Singh, Mahavir (2009)
    The enzymes of the antigen 85 complex (Ag85A, B, and C) possess mycolyltransferase activity and catalyze the synthesis of the most abundant glycolipid of the mycobacterial cell wall, the cord factor. The cord factor (trehalose 6,6'-dimycolate, TDM) is essential for the integrity of the mycobacterial cell wall and pathogenesis of the bacillus. Thus, TDM biosynthesis is regarded as a potential drug target for control of Mycobacterium tuberculosis infections. Trehalose 6,6'-dimycolate (TDM) is s...

    Ciprofloxacin-loaded lipid-core nanocapsules as mucus penetrating drug delivery system intended for the treatment of bacterial infections in cystic fibrosis.

    Torge, Afra; Wagner, Stefanie; Chaves, Paula S; Oliveira, Edilene G; Guterres, Silvia S; Pohlmann, Adriana R; Titz, Alexander; Schneider, Marc; Beck, Ruy C R (2017)
    Treatment of bacterial airway infections is essential for cystic fibrosis therapy. However, effectiveness of antibacterial treatment is limited as bacteria inside the mucus are protected from antibiotics and immune response. To overcome this biological barrier, ciprofloxacin was loaded into lipid-core nanocapsules (LNC) for high mucus permeability, sustained release and antibacterial activity. Ciprofloxacin-loaded LNC with a mean size of 180nm showed a by 50% increased drug permeation through...
  • No data provider research data found
  • Latest Documents Timeline

    Chart is loading... It may take a bit of time. Please be patient and don't reload the page.

    Document Types

    Chart is loading... It may take a bit of time. Please be patient and don't reload the page.

    Funders in data provider publications

    Chart is loading... It may take a bit of time. Please be patient and don't reload the page.

    Projects with most Publications

    Chart is loading... It may take a bit of time. Please be patient and don't reload the page.

Share - Bookmark